PT -期刊文章盟拉斐尔Bernard-Valnet AU -克里斯汀Lebrun Frenay AU -伯特兰Audoin AU -伯特兰Bourre AU -苏菲Pittion盟Sandrine Wiertlewski AU -罗曼·Marignier盟乔纳森Ciron AU -布鲁诺布罗谢AU -大卫Brassat盟海琳Zephir TI -利妥昔单抗作为一线治疗视神经节Neuromyelitis:效率和耐受性(P5.258) DP - 2015年4月06 TA -神经病学PG - P5.258 VI - 84 IP - 14补充4099 - //www.ez-admanager.com/content/84/14_Supplement/P5.258.short 4100 - //www.ez-admanager.com/content/84/14_Sup首页plement/P5.258.full所以Neurology2015 4月06;84 AB -目的:评估如果使用利妥昔单抗作为第一线治疗视神经节neuromyelitis(动)是安全的和有效的。背景:动是一种罕见的中枢神经系统炎症性疾病的特点是集视神经炎和横向脊髓炎。自身抗体针对水通道蛋白4 (AQP4)中发现超过75 [percnt]动病人。最近积极性anti-MOG AQ4 -患者的抗体被描述和可能感兴趣的动诊断和监测。这种体液免疫反应被证明是致病性给予强有力的证据治疗动与生物制剂如利妥昔单抗(单克隆抗体针对B细胞(anti-CD20)。设计/方法:这个多中心回顾性研究中,我们为32法国动病人接受利妥昔单抗作为一线治疗前(没有免疫调节或免疫抑制治疗,防止复发)。我们的主要目标是确定relapse-free-patients的速率。次要的目标是:改变复发年率(ARR), eds和副作用描述变化。结果:在启动,动病人在我们群是41,2±13岁,平均疾病持续时间为6.5个月(1 - 410),性别比例(F / M)为4.5。 Among these patients 84[percnt] were positive for AQP4 antibodies and the mean EDSS was 5.8 ± 2.4. After a median follow-up of 19 months [6-75] under rituximab, twenty-five (78[percnt]) patients were relapse-free. Patients presented a mean ARR of 0.1 ± 0.8 and a mean EDSS of 4.06 ± 2.7 at last follow-up. In the subgroup that properly received rituximab reinfusion every 6 months (n=28), the rate of relapse free patients raises to 82[percnt]. CONCLUSIONS: In our cohort and with our protocol (first line therapy and every 6 months consolidation) RTX was highly efficient and safe for NMO treatment. Our study suggests that RTX may be used as first line therapy in NMO spectrum disorder.Disclosure: Dr. Bernard-Valnet has nothing to disclose. Dr. Lebrun has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Genazyme, Almirall, Allergan, Inc., Novartis and Sanofi as a speaker. Dr. Audoin has nothing to disclose. Dr. Bourre has nothing to disclose. Dr. Pittion has nothing to disclose. Dr. Wiertlewski has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Ciron has nothing to disclose. Dr. Brochet has received personal compensation for activities with Bayer HealthCare, Novartis, Merck Serono, Biogen Idec, Genzyme, and Teva. Dr. BRASSAT has nothing to disclose. Dr. Zephir has received personal compensation for activities with Biogen Idec, Bayer Schering Pharma, Merck & Co., Inc., Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis.Wednesday, April 22 2015, 2:00 pm-6:30 pm